GlassScriptPhysician profile
Melissa Randazzo
NPI 1053831479
$3,169.26
in general payments reported to CMS, 2019-2025
25 companies · $608 in 2025
The $608 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.85 · 2020: $527 · 2021: $515 · 2022: $359 · 2023: $352 · 2024: $767 · 2025: $608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,727.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $441.93 | 2020-2025 | Bexsero, Penmenvy, Pediarix |
| Kaleo, INC. | $298.66 | 2020-2024 | Auvi-Q |
| Neos Therapeutics, LP | $257.57 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Cranial Technologies, INC | $218.47 | 2019-2025 | Doc Band |
| Pfizer INC. | $207.94 | 2019-2023 | |
| Abbvie INC. | $192.95 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $186.93 | 2020-2025 | Gardasil 9, Vaxelis, Gardasil |
| Supernus Pharmaceuticals, INC. | $164.66 | 2021-2025 | Qelbree |
| Tris Pharma INC | $151.04 | 2020-2025 | Dyanavel Xr |
| Corium, LLC | $146.63 | 2024-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $144.39 | 2024 | |
| Tempus Ai, INC | $126.66 | 2024 | |
| Collegium Pharmaceutical, INC. | $112.55 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $99.91 | 2024-2025 | |
| Aytu Biopharma, INC. | $99.81 | 2020-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $60.00 | 2020-2021 | |
| Seqirus USA INC | $49.26 | 2022-2025 | Flucelvax |
| Arbor Pharmaceuticals, INC. | $44.77 | 2020 | |
| Exeltis, USA INC. | $33.58 | 2024 | Slynd |
| Alk-Abello, INC | $33.42 | 2025 | Ragwitek, Odactra, Grastek |
| Ars Pharmaceuticals Operations, INC. | $32.68 | 2025 | Neffy |
| Botanix Sb INC | $18.28 | 2025 | Sofdra |
| Kyowa Kirin, INC. | $18.15 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $14.95 | 2022 | |
| Sobi, INC | $14.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Randazzo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.